Cochrane · systematic review · CD005573
Probiotics for induction of remission in ulcerative colitis
Kaur, L, Gordon, M, Baines, PA, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
15
current version
GRADE rated
10
No studies
5
Included studies
NR
No studies 5 · 33.3%Ungraded 0 · 0%Very low 5 · 33.3%Low 5 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Probiotics compared to placebo for induction of remission in ulcerative colitis
Population: people with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Probiotics vs placebo | RR 1.73 [1.19, 2.54] | 9 studies · 594 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Disease improvement (based on clinical scores) Probiotics vs placebo | RR 2.29 [1.13, 4.63] | 2 studies · 54 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Minor adverse events Probiotics vs placebo | RR 1.04 [0.42, 2.59] | 7 studies · 520 participants | Very low Downgraded: risk of bias, inconsistency |
Serious adverse events Probiotics vs placebo | RR 0.09 [0.01, 1.66] | 7 studies · 526 participants | Very low Downgraded: risk of bias, imprecision |
Withdrawal due to adverse events Probiotics vs placebo | RR 0.85 [0.42, 1.72] | 4 studies · 401 participants | Low Downgraded: imprecision |
Probiotics compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis
Population: people with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical remission Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 0.92 [0.73, 1.16] | 1 study · 116 participants | Low Downgraded: imprecision |
Minor adverse events Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 1 | 2 studies · 192 participants | Very low Downgraded: imprecision |
Serious adverse events Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 0.21 [0.01, 4.22] | 1 study · 116 participants | Very low Downgraded: imprecision |
Withdrawal due to adverse events Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 0.21 [0.01, 4.22] | 1 study · 116 participants | Very low Downgraded: imprecision |
Disease improvement Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | NR | No studies |
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) compared to 5‐aminosalicylic acid (5‐ASA) (mesalazine) for induction of remission in ulcerative colitis
Population: people with active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Remission Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | RR 1.22 [1.01, 1.47] | 1 study · 84 participants | Low Downgraded: risk of bias, imprecision |
Disease improvement Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | NR | No studies |
Minor adverse events Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | NR | No studies |
Serious adverse events Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | NR | No studies |
Withdrawal due to adverse events Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) | no estimate extracted | NR | No studies |